BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 34642088)

  • 1. Development of an IgG-Fc fusion COVID-19 subunit vaccine, AKS-452.
    Alleva DG; Delpero AR; Scully MM; Murikipudi S; Ragupathy R; Greaves EK; Sathiyaseelan T; Haworth JR; Shah NJ; Rao V; Nagre S; Lancaster TM; Webb SS; Jasa AI; Ronca SE; Green FM; Elyard HA; Yee J; Klein J; Karnes L; Sollie F; Zion TC
    Vaccine; 2021 Oct; 39(45):6601-6613. PubMed ID: 34642088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I interim results of a phase I/II study of the IgG-Fc fusion COVID-19 subunit vaccine, AKS-452.
    Janssen YF; Feitsma EA; Boersma HH; Alleva DG; Lancaster TM; Sathiyaseelan T; Murikipudi S; Delpero AR; Scully MM; Ragupathy R; Kotha S; Haworth JR; Shah NJ; Rao V; Nagre S; Ronca SE; Green FM; Aminetzah A; Sollie F; Kruijff S; Brom M; van Dam GM; Zion TC
    Vaccine; 2022 Feb; 40(9):1253-1260. PubMed ID: 35115195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized phase I/II safety and immunogenicity study of the Montanide-adjuvanted SARS-CoV-2 spike protein-RBD-Fc vaccine, AKS-452.
    Feitsma EA; Janssen YF; Boersma HH; van Sleen Y; van Baarle D; Alleva DG; Lancaster TM; Sathiyaseelan T; Murikipudi S; Delpero AR; Scully MM; Ragupathy R; Kotha S; Haworth JR; Shah NJ; Rao V; Nagre S; Ronca SE; Green FM; Aminetzah A; Sollie F; Kruijff S; Brom M; van Dam GM; Zion TC
    Vaccine; 2023 Mar; 41(13):2184-2197. PubMed ID: 36842886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elicitation of potent neutralizing antibodies in obese mice by ISA 51-adjuvanted SARS-CoV-2 spike RBD-Fc vaccine.
    Li CJ; Jiang CL; Chao TL; Lin SY; Tsai YM; Chao CS; Su YT; Chen CJ; Chang SY; Lin FJ; Chang SC
    Appl Microbiol Biotechnol; 2023 May; 107(9):2983-2995. PubMed ID: 36988669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced elicitation of potent neutralizing antibodies by the SARS-CoV-2 spike receptor binding domain Fc fusion protein in mice.
    Liu X; Drelich A; Li W; Chen C; Sun Z; Shi M; Adams C; Mellors JW; Tseng CT; Dimitrov DS
    Vaccine; 2020 Oct; 38(46):7205-7212. PubMed ID: 33010978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccine based on folded receptor binding domain-PreS fusion protein with potential to induce sterilizing immunity to SARS-CoV-2 variants.
    Gattinger P; Kratzer B; Tulaeva I; Niespodziana K; Ohradanova-Repic A; Gebetsberger L; Borochova K; Garner-Spitzer E; Trapin D; Hofer G; Keller W; Baumgartner I; Tancevski I; Khaitov M; Karaulov A; Stockinger H; Wiedermann U; Pickl WF; Valenta R
    Allergy; 2022 Aug; 77(8):2431-2445. PubMed ID: 35357709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant SARS-CoV-2 spike S1-Fc fusion protein induced high levels of neutralizing responses in nonhuman primates.
    Ren W; Sun H; Gao GF; Chen J; Sun S; Zhao R; Gao G; Hu Y; Zhao G; Chen Y; Jin X; Fang F; Chen J; Wang Q; Gong S; Gao W; Sun Y; Su J; He A; Cheng X; Li M; Xia C; Li M; Sun L
    Vaccine; 2020 Jul; 38(35):5653-5658. PubMed ID: 32651113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CHO-produced RBD-Fc subunit vaccines with alternative adjuvants generate immune responses against SARS-CoV-2.
    Laotee S; Duangkaew M; Jivapetthai A; Tharakhet K; Kaewpang P; Prompetchara E; Phumiamorn S; Sapsutthipas S; Trisiriwanich S; Somsaard T; Roytrakul S; Duangkhae P; Ongpipattanakul B; Limpikirati P; Pornputtapong N; Arunmanee W
    PLoS One; 2023; 18(7):e0288486. PubMed ID: 37450510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvanting a subunit COVID-19 vaccine to induce protective immunity.
    Arunachalam PS; Walls AC; Golden N; Atyeo C; Fischinger S; Li C; Aye P; Navarro MJ; Lai L; Edara VV; Röltgen K; Rogers K; Shirreff L; Ferrell DE; Wrenn S; Pettie D; Kraft JC; Miranda MC; Kepl E; Sydeman C; Brunette N; Murphy M; Fiala B; Carter L; White AG; Trisal M; Hsieh CL; Russell-Lodrigue K; Monjure C; Dufour J; Spencer S; Doyle-Meyers L; Bohm RP; Maness NJ; Roy C; Plante JA; Plante KS; Zhu A; Gorman MJ; Shin S; Shen X; Fontenot J; Gupta S; O'Hagan DT; Van Der Most R; Rappuoli R; Coffman RL; Novack D; McLellan JS; Subramaniam S; Montefiori D; Boyd SD; Flynn JL; Alter G; Villinger F; Kleanthous H; Rappaport J; Suthar MS; King NP; Veesler D; Pulendran B
    Nature; 2021 Jun; 594(7862):253-258. PubMed ID: 33873199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
    Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
    J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response.
    Liu Z; Xu W; Xia S; Gu C; Wang X; Wang Q; Zhou J; Wu Y; Cai X; Qu D; Ying T; Xie Y; Lu L; Yuan Z; Jiang S
    Signal Transduct Target Ther; 2020 Nov; 5(1):282. PubMed ID: 33247109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a Recombinant RBD Subunit Vaccine for SARS-CoV-2.
    Sun YS; Zhou JJ; Zhu HP; Xu F; Zhao WB; Lu HJ; Wang Z; Chen SQ; Yao PP; Jiang JM; Zhou Z
    Viruses; 2021 Sep; 13(10):. PubMed ID: 34696367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.
    Yang Y; Zang J; Xu S; Zhang X; Yuan S; Wang H; Lavillette D; Zhang C; Huang Z
    Viruses; 2021 Jul; 13(8):. PubMed ID: 34452287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical evaluation of a plant-derived SARS-CoV-2 subunit vaccine: Protective efficacy, immunogenicity, safety, and toxicity.
    Shanmugaraj B; Khorattanakulchai N; Panapitakkul C; Malla A; Im-Erbsin R; Inthawong M; Sunyakumthorn P; Hunsawong T; Klungthong C; Reed MC; Kemthong T; Suttisan N; Malaivijitnond S; Srimangkornkaew P; Klinkhamhom A; Manopwisedjaroen S; Thitithanyanont A; Taychakhoonavudh S; Phoolcharoen W
    Vaccine; 2022 Jul; 40(32):4440-4452. PubMed ID: 35697573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Receptor binding domain proteins of SARS-CoV-2 variants produced in Nicotiana benthamiana elicit neutralizing antibodies against variants of concern.
    Khorattanakulchai N; Manopwisedjaroen S; Rattanapisit K; Panapitakkul C; Kemthong T; Suttisan N; Srisutthisamphan K; Malaivijitnond S; Thitithanyanont A; Jongkaewwattana A; Shanmugaraj B; Phoolcharoen W
    J Med Virol; 2022 Sep; 94(9):4265-4276. PubMed ID: 35615895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Construction and immunogenic studies of a mFc fusion receptor binding domain (RBD) of spike protein as a subunit vaccine against SARS-CoV-2 infection.
    Qi X; Ke B; Feng Q; Yang D; Lian Q; Li Z; Lu L; Ke C; Liu Z; Liao G
    Chem Commun (Camb); 2020 Aug; 56(61):8683-8686. PubMed ID: 32613971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments--the importance of immunofocusing in subunit vaccine design.
    Ma C; Wang L; Tao X; Zhang N; Yang Y; Tseng CK; Li F; Zhou Y; Jiang S; Du L
    Vaccine; 2014 Oct; 32(46):6170-6176. PubMed ID: 25240756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
    Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
    Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel STING agonist-adjuvanted pan-sarbecovirus vaccine elicits potent and durable neutralizing antibody and T cell responses in mice, rabbits and NHPs.
    Liu Z; Zhou J; Xu W; Deng W; Wang Y; Wang M; Wang Q; Hsieh M; Dong J; Wang X; Huang W; Xing L; He M; Tao C; Xie Y; Zhang Y; Wang Y; Zhao J; Yuan Z; Qin C; Jiang S; Lu L
    Cell Res; 2022 Mar; 32(3):269-287. PubMed ID: 35046518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of nanoparticle vaccines utilizing designed Fc-binding homo-oligomers and RBD-Fc of SARS-CoV-2.
    Liang Y; Xiao W; Peng Y; Zhang S; Dong J; Zhao J; Wang Y; Zhang M; Liu Z; Yu B
    Antiviral Res; 2024 Jul; 227():105917. PubMed ID: 38782067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.